- Market Capitalization, $K 13,235,338
- Shares Outstanding, K 687,550
- Annual Sales, $ 5,711 M
- Annual Income, $ 700,160 K
- 60-Month Beta 0.61
- Price/Sales 2.23
- Price/Cash Flow 11.14
- Price/Book 1.55
|Period||Period Low||Period High||Performance|
| || |
+1.71 (+9.93%)since 11/02/20
| || |
+2.93 (+18.31%)since 09/02/20
| || |
-3.72 (-16.42%)since 12/02/19
Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.
The rising investments for effective medicines is predicted to drive the global Cell Surface Markers Market during the forecast period, states Fortune Business Insights in a report. The growing cognizance...
, /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more than 100 years of history contributing...
, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and provider of technologies and services for hospitals, clinics and compounding...
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STAF, SOLO, GRFS, NBEV, and NCLH.
, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...
- - - - , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's leading producers of plasma-derived medicines, today announced the closing...
, and , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced...